Close menu




February 27th, 2025 | 07:10 CET

Elon Musk, Donald Trump, and the GOLD MARKET! Barrick Gold and First Nordic Metals are rising! Even Novo Nordisk shares are in a gold rush!

  • Mining
  • Gold
  • Commodities
  • Biotechnology
Photo credits: pixabay.com

No gold in Fort Knox? This crazy theory is currently being fueled by Donald Trump and Elon Musk. To uncover the secrets of the US gold reserve location, the two best friends plan to visit the site in person soon. Meanwhile, price targets of USD 3,500 for the precious metal are doing the rounds. Even Barrick Gold's stock is rising! Can the giant really solve a big problem? First Nordic Metals appears to be a more promising gold investment. The Company is focused on the European gold mining region of the future. The stock is only just being discovered by the capital market, and it is showing a lot of momentum. Novo Nordisk is also part of the "gold rush". The Norwegians are making billions with their weight loss injection. Problems at a competitor are causing a price jump.

time to read: 4 minutes | Author: Fabian Lorenz
ISIN: BARRICK GOLD CORP. | CA0679011084 , FIRST NORDIC METALS CORP | CA33583M1077 , NOVO NORDISK A/S | DK0062498333

Table of contents:


    Nick Luksha, President, Prospect Ridge Resources
    "[...] As we look at four or more zones in more detail from the beginning, investors can expect a continuous news flow that will underscore our vision of the Holy Grail project as a giant opportunity. [...]" Nick Luksha, President, Prospect Ridge Resources

    Full interview

     

    First Nordic Metals: A stock with momentum and upside potential

    Shares and industry with momentum, a convincing chart, and promising drilling programs suggest that First Nordic Metals will continue to rise in price. The gold explorer with projects in Sweden and Finland is increasingly developing from a hidden gem to a high-flyer in the new year. The share is only just being discovered by the capital market and is now being actively traded on German stock exchanges.

    The Company aims to become the new European gold producer. To this end, it is focusing on deposits in Scandinavia and is operating at full speed. As CEO Taj Singh recently said: "*Sweden and Finland are currently among the most attractive, fascinating, and least explored regions for resource exploration in the world. *With a strong resource base and a fully funded, extensive drilling program in several high-potential target areas, we are well positioned for an exciting 2025 and for expanding Europe's gold mining region of the future."** In line with this operational focus, the Company plans to list its shares on the Swedish Nasdaq First North Growth exchange in March.

    In northern Sweden, First Nordic is currently developing the Barsele gold project in a joint venture with the gold group Agnico Eagle. In the immediate vicinity of this flagship project, the gold pearl also has the Paubäcken, Storjuktan, and Klippen projects. All properties together cover an area of 104,000 hectares within a known regional gold belt. First Nordic last reported on the drilling program at the Paubäcken project. It has a scope of 5,150 m. Twenty-four diamond drill holes are planned to test an identified structural corridor with a length of 3 km. Last year, a discovery hole returned 2.4 g/t gold ("Au") over 22.5 m.

    A rising gold price and operational news flow should further boost the share price.

    Barrick: Trump and Musk stir up the gold market

    Donald Trump and Elon Musk are not only involved in Bitcoin, but they have also discovered gold. More specifically, the US gold reserves in Fort Knox. Initially, the Tesla boss joined the discussion on his social network about whether the legendary Fort Knox actually stores gold. The theory that the US gold reserves are significantly smaller or do not even exist is a popular conspiracy theory. The billionaire intends to investigate this. Last weekend, US President Donald Trump also fueled the topic. In his speech at the Conservative Political Action Committee (CPAC) conference, he announced that he would visit Fort Knox with Elon Musk. It would not be surprising if the two made a media spectacle of the visit, in the style of the James Bond film, Goldfinger.

    At the event, Trump says, among other things: "We are also going to go to Fort Knox. I will go with Elon. Would anyone like to join us? Because we want to see if the gold is still there. We want to see it. We are opening this Fort Knox. Wouldn't it be terrible if we opened it and there was no gold? So we're going to open those doors. We're going to take a look. And if there are 27 tons of gold, we will be very happy. I don't know how we are going to measure it, but that's okay. We want to see lots of nice, shiny gold at Fort Knox."

    It is difficult to assess how much Trump and Musk influence the price of gold. What is clear is that the precious metal continues its strong performance from 2024 into the new year. Although it has not yet broken through the USD 3,000 mark, it will likely do so soon. In any case, experts are bullish. Most recently, Bank of America had set a target price of USD 3,500. The drivers are well known: geopolitical risks, inflation, uncertainty – including tariffs – from Donald Trump, as well as purchases by China and other central banks.

    Driven by the gold price, Barrick Gold's shares have now also jumped. Various media outlets report that the beleaguered industry giant may be able to resolve the escalating dispute surrounding the mega-mine in Mali. An agreement with the Malian government is said to be close to being signed. However, there has been no official statement from Barrick or Mali's mining ministry to date.

    Novo Nordisk: Bad news causes share price to jump

    Novo Nordisk is also in a "gold rush". In any case, the Company is making a killing not only with insulin but also with the weight-loss injection Wegovy. The correction in the share price appears to have ended. On Tuesday alone, the security gained over 4%. Within the last five trading days, the gain is almost 15% and is attempting to form an upward trend.

    There was a good reason for this week's price jump: The US company Hims & Hers Health announced in its earnings report that it would stop selling certain weight-loss drugs. The drugs, based on the active ingredient Semaglutide, were seen as new competition for the top dogs Novo Nordisk and Eli Lilly. Although the CFO of Hims & Hers Health emphasized that they would continue to offer personalized versions of these drugs, stock market players were shocked. The stock lost over 20% of its value following the news.


    Barrick Gold seems to be working on a solution in Mali, but even if an agreement is reached, it remains to be seen how much it will cost the Company and how sustainable peace will be. In contrast, the stock of First Nordic Metals appears to be more interesting. The Company is active in stable countries, already has a billion-dollar corporation on board, and can accelerate the development of its projects. The Novo Nordisk share seems to have found the bottom and looks set to work on a new upward trend.


    Conflict of interest

    Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") may hold shares or other financial instruments of the aforementioned companies in the future or may bet on rising or falling prices and thus a conflict of interest may arise in the future. The Relevant Persons reserve the right to buy or sell shares or other financial instruments of the Company at any time (hereinafter each a "Transaction"). Transactions may, under certain circumstances, influence the respective price of the shares or other financial instruments of the Company.

    In addition, Apaton Finance GmbH is active in the context of the preparation and publication of the reporting in paid contractual relationships.

    For this reason, there is a concrete conflict of interest.

    The above information on existing conflicts of interest applies to all types and forms of publication used by Apaton Finance GmbH for publications on companies.

    Risk notice

    Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and the like on news.financial. These contents are exclusively for the information of the readers and do not represent any call to action or recommendations, neither explicitly nor implicitly they are to be understood as an assurance of possible price developments. The contents do not replace individual expert investment advice and do not constitute an offer to sell the discussed share(s) or other financial instruments, nor an invitation to buy or sell such.

    The content is expressly not a financial analysis, but a journalistic or advertising text. Readers or users who make investment decisions or carry out transactions on the basis of the information provided here do so entirely at their own risk. No contractual relationship is established between Apaton Finance GmbH and its readers or the users of its offers, as our information only refers to the company and not to the investment decision of the reader or user.

    The acquisition of financial instruments involves high risks, which can lead to the total loss of the invested capital. The information published by Apaton Finance GmbH and its authors is based on careful research. Nevertheless, no liability is assumed for financial losses or a content-related guarantee for the topicality, correctness, appropriateness and completeness of the content provided here. Please also note our Terms of use.


    Der Autor

    Fabian Lorenz

    For more than twenty years, the Cologne native has been intensively involved with the stock market, both professionally and privately. He is particularly passionate about national and international small and micro caps.

    About the author



    Related comments:

    Commented by Nico Popp on April 25th, 2025 | 07:20 CEST

    US biotechs under pressure – Where opportunities now lie: BioNTech, Pfizer, and Vidac Pharma

    • Biotechnology
    • Biotech
    • Pharma

    The biotech world is in turmoil. The dispute between US President Donald Trump and the elite Harvard University is just the tip of the iceberg – thousands of researchers in the US are upset about the interference in their academic freedom. Research funding is being cut because of supposedly incorrect wording in applications. Entire degree programs are being put on hold because they do not fit into the worldview of the new US administration. The National Security Commission on Emerging Biotechnology (NSCEB) is warning of dire consequences for the US economy. Is the United States losing its status as a biotech mecca?

    Read

    Commented by Fabian Lorenz on April 25th, 2025 | 07:00 CEST

    RENK BEFORE TAKEOVER? Will Evotec and AI gem NetraMark be swallowed up?

    • Biotechnology
    • Biotech
    • Defense

    Is RENK on the verge of a takeover? In any case, the antitrust authorities have approved the entry of a new major shareholder. Could the takeover of the gearbox manufacturer herald a consolidation in the European defense industry, as announced by the head of Hensoldt? So far, there have only been small acquisitions, such as those of Rheinmetall. There is also movement in the pharmaceutical and biotech sectors. The Trump tariffs are shaking up the industry. NetraMark's AI software helps reduce costs and save time in drug research. The AI insider tip's stock still appears cheap and could skyrocket amid takeover speculation. Evotec has also been repeatedly mentioned as a takeover candidate. Yesterday, a large milestone payment was reported. How are the shares performing?

    Read

    Commented by Nico Popp on April 24th, 2025 | 07:30 CEST

    Germany Inc. as the last hope? Volkswagen, Bayer, Globex Mining

    • Mining
    • Gold
    • Electromobility
    • Pharma

    Germany's economy is facing its third consecutive year of contraction. The automotive industry is struggling with competition from China, and Bayer is grappling with past acquisitions, looming tariffs, and other challenges. Now, Bayer shareholders are even being asked to inject new capital. Is the German industry working with politicians to find long-term solutions? Not a chance! The days of Germany Inc. seem to be over. We look at how investors can seize opportunities in this complex situation.

    Read